We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

2331:HKEXLi Ning Company Limited Analysis

Data as of 2026-09-07 - not real-time

HK$13.75

Latest Price

5/10Risk

Risk Level: Medium

Executive Summary

Li Ning Company Limited trades at HKD 13.75, with its short-term moving averages sitting below the longer-term ones — a bearish trend structure. Over a rolling month the price has lost 5.9%. With RSI at 42.5 the momentum picture is neutral, alongside a bullish MACD signal. Price has been bracketed by support at HKD 13.04 and resistance at HKD 15.04.
On valuation the read is undervalued — an earnings multiple of 10.1, absent a reliable peer benchmark. Analyst price targets sit 37.9% above the current price. Revenue is growing at 2.8% on a 10.0% profit margin. The 4.99% dividend yield looks covered by current payout levels.
The composite risk read is 5/10, putting it in moderate territory. With 30-day volatility of 25.7%, a beta of 0.28 and a maximum drawdown of 42.4%, position sizing matters here. The wider market backdrop reads extreme greed at 94 on the fear-greed composite.
The horizons diverge: hold near-term but buy on a long view, at 5/10 conviction over the longer horizon.

Top Market Events

Firmly Implementing the “Single Brand, Multi-categories, Diversified Channels” Strategy; Super BOOM Capsule...Detailed price information for Li Ning Co.Li Ning Company Limited Announces 2026 Interim Results.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 2/10

Key Factors

  • Short-term moving averages stacked below long-term ones
  • Trading below the 200-day average of 18.23
  • MACD momentum is positive

Medium Term

1–3 years
Neutral
Model confidence: 3/10

Key Factors

  • Short-term moving averages stacked below long-term ones
  • Trading below the 200-day average of 18.23
  • Analyst targets imply +37.9% versus the current price

Long Term

> 3 years
Positive
Model confidence: 5/10

Key Factors

  • Analyst targets imply +37.9% versus the current price
  • P/E ratio of 10.1
  • Dividend yield of 4.99%

Key Metrics & Analysis

Financial Health

Revenue Growth2.80%
Profit Margin10.04%
P/E Ratio10.1
ROE10.80%
ROA6.70%
Debt/Equity6.91
P/B Ratio1.1
Op. Cash FlowHK$3.4B
Free Cash FlowHK$2.2B

Technical Analysis

TrendBearish
RSI42.5
SupportHK$13.04
ResistanceHK$15.04
MA 20HK$13.94
MA 50HK$14.50
MA 200HK$18.23
MACDBullish
VolumeIncreasing
Fear & Greed Index94.11

Valuation

Fair ValueHK$17.58
Target PriceHK$18.96
Upside/Downside37.86%
GradeUndervalued
TypeValue
Dividend Yield4.99%

Risk Assessment

Beta0.28
Volatility25.68%
Sector RiskHigh
Reg. RiskLow
Geo RiskHigh
Currency RiskHigh
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.